Caroline Behler is an Oncology physician affiliated with California Pacific Medical Center. OpenAlex indexes 29 publications with 643 citations (h-index 10); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2100 Webster St Ste 225
San Francisco, CA 941152376
Telephone
415-923-3012Registry record last updated 28 Feb 2013.
Clinical trials
- A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant
Sponsor: University of California, San Francisco
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
65 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Celgene CorporationProgram year20258 payments
- PFIZER INC.Program year20256 payments
- ABBVIE INC.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
43.3%Erythropoiesis-stimulating Agent43%Darbepoetin alfa100%Part B, office-administered≥27 patientsFactor Xa inhibitor0.2%Eliquis56%Xarelto44%Part D<11 patients+ 3 more classes in this area
Cancer & immunology
34.3%CD38-directed Cytolytic Antibody18.9%Daratumumab100%Part B, office-administered≥11 patientsPD-1 inhibitor13%Pembrolizumab100%Part B, office-administered≥14 patients+ 14 more classes in this area
Musculoskeletal
14.8%RANK Ligand Inhibitor14.8%Denosumab99%Xgeva1%Part D + Part B<11 patientsXanthine oxidase inhibitor0%Allopurinol100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
John Chan, MD
California Pacific Medical Center
Kenneth Binmoeller, MD
California Pacific Medical Center
Kenneth Laxer, MD
California Pacific Medical Center
Yvonne Cheng, MD
California Pacific Medical Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”